Cipla a major drug company recently announces launches of inhalation therapy product ‘Niveoli’ in India.
Niveoli is used in respiratory inhalation therapy that addresses an unmet need associated with obstructive airway diseases (OAD) such as asthma
and chronic obstructive pulmonary disorder (COPD), Cipla said in a BSE filing.
Cipla said Niveoli, extra-fine particle beclomethasone-formoterol combination hydrofluoroalkane (HFA) inhaler
for adults, targets drug delivery to the small airways.
“We see our market leadership, as well as the range and depth of our R&D and manufacturing capabilities in this therapy as a privilege and a responsibility to do more for patients,” Cipla Head – India business Nikhil Chopra, said.
Shares of Cipla were trading 0.40 per cent higher at Rs 546.55 apiece on BSE.